| Revenue growth | Consolidated revenue +9.8% YoY to ₹318 Cr; one-offs not discussed. |
|---|---|
| Margins | Consolidated EBITDA margin 14.6% vs 15.9%; standalone 18.2% vs 19.5%. |
| Demand visibility | Occupancy up to 52% (+400 bps); insured and government patient mix rising. |
| Management confidence | Overly optimistic: 'healthy improvement across all KPIs' despite margin and profit decline. |
Growth
Revenue ₹318 Cr, +9.8%; EBITDA +0.8%, PBT −14% to ₹16.5 Cr. Standalone revenue +9.1%; Gurgaon +50%.
Outlook
FY27: double-digit top-line growth, ETR ~45-50%, Gurgaon cash break-even near Q4 exit, lower net debt. No hard EBITDA or PAT numbers.
Risks
Subsidiary losses persist, pulling consolidated profit down. Mumbai approvals delayed; evasive on POSO revenue. NPPA price relief unconfirmed.
Last quarter's promises, checked
Delivered
- Guided net debt stable/reducing → ₹463 Cr to ₹458 Cr (= BEAT)
Partly delivered
- Guided Gurgaon PBT-positive by Q3–Q4 FY27 → cash break-even near Q4 exit; revenue +50% YoY (= PARTIAL)
Missed
- Guided standalone EBITDA margin ~20% FY27 → Q2 18.2%, below Q1 18.4% (= MISS)
- Guided MedTech India growth sustained (Q1 +130% YoY) → +40% YoY (= MISS)
- Guided gross margin +100–200 bps/qtr → EBITDA margin 14.5% to 14.6%, +10 bps; gross margin not disclosed (= MISS)
Earnings Call Transcript filed with NSE, NSE: SHALBY. Summary written with AI assistance from the document.
Shalby Ltd: key numbers
- Share price
- ₹122.01
- Market cap
- ₹1,318 Cr
- Revenue (annual)
- ₹1,141 Cr
- Net profit (annual)
- ₹37.39 Cr
- P/E (TTM)
- 33.6×Sector 53.8×
- Promoter holding
- 74.33%+0.00% QoQ
- FII holding
- 4.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shalby Ltd
All →Shalby Other Announcement
Shalby Limited disclosed under Regulation 30(5) that the board authorised KMP personnel for materiality determination. Mr. Tushar Shah's designation was revised after his appointment as Executive Director.
Shalby Investor Presentation: Key Takeaways
Consolidated Q2 FY27 revenue ₹3,182mn (+9.8% YoY), EBITDA flat at ₹464mn, margin 14.6%, PAT ₹79mn (+8.3%). Standalone PAT +19%; growth driven by International and occupancy.
Shalby Annual General Meeting
Shalby Ltd seeks shareholder approval via postal ballot to appoint Shanay Vikram Shah and Tushar Shah as directors. E-voting runs November 5 to December 4, 2026.
Shalby Management Change
Shalby Limited appointed Mr. Tushar Shah as Executive Director for five years, effective November 3, 2026, subject to shareholder approval. The change is a senior management appointment.
- Execution
- 5 years from November 3, 2026
Shalby Q2 FY27 Results: Net Profit ₹7.9 Cr, Up 8.2% YoY
Shalby Ltd reported revenue from operations of ₹313.2 Cr (+9.7% YoY) and net profit of ₹7.9 Cr (+8.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹7.9 Cr · +8.2% YoY
Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.